By Ross Marchand | Taxpayer Protection Alliance - June 15, 2021 at 09:33AM
There is a tempest brewing at the Food and Drug Administration (FDA). Recently, the agency opted to approve aducanumab, which is the first drug on the market potentially capable of slowing down Alzheimer’s disease. The medication was approved amid considerable…
Read Entire Article Here: Watchdog National News
via IFTTT
